SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Data on valve durability with transcatheter aortic valve replacement are reassuring at 7 years, with implications for ...

During valve-in-valve TAVI procedures using the Sapien 3 balloon-expandable valve (Edwards Lifesciences) as the second prosthesis, downsizing and underexpansion are frequently observed, particularly ...

In mostly women with small aortic annuli, self-expanding valves maintained superior hemodynamics and far lower valve ...

Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation ...

LONDON, England—Having a small or large annuli does not appear to make a difference for low-risk patients with symptomatic severe aortic stenosis, who have similar 5-year clinical and quality-of-life ...

Many believe that transcatheter aortic valve implantation is one of the most exciting and lucrative new technologies to hit the market providing an option for patients to sick to undergo open heart ...

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were ...

Edwards Lifesciences gains attention after fresh valve data as structural heart devices, valuation debate, and healthcare ...